Except saxagliptin, the safety of all DPP-4 inhibitors has been proven in patients with any level of eGFR; therefore, DPP-4 inhibitors may be more suitable than insulin for patients with severe renal insufficiency [124]. Here, DPP4 is linked to Renal insufficiency.